Year Founded
2020
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Autologous cell therapyRegulatory T cell therapy

Abata Therapeutics General Information

Lead program ABA-101 for progressive MS is initiating Phase 1 trial, second program ABA-201 for type 1 diabetes is in IND-enabling studies

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Watertown, Massachusetts
United States

Drug Pipeline

ABA-101
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Abata Therapeutics's pipeline data

Book a demo

Key Partnerships

Bristol Myers Squibb

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Abata Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Abata Therapeutics's complete valuation and funding history, request access »

Abata Therapeutics Investors

Third Rock Ventures
Investor Type: Venture Capital
Holding: Minority
Lightspeed Venture Partners
Investor Type: Venture Capital
Holding: Minority
MPM Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »